×

Do you want to link to this External Site and leave Amgen.co.kr?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this Amgen Site and leave Amgen.co.kr?

YOU ARE NOW LEAVING AMGEN KOREA'S WEB SITE. Amgen Korea takes takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

BLINCYTO® 35 μg

  • Product Name (Korean) 블린사이토주 35μg/바이알
  • Product Name (Engilsh) BLINCYTO® 35μg /vial
  • Active Ingredient (Korean) 블리나투모맙
  • Active Ingredient (English) blinatumomab
  • Treatment Treatment of acute lymphoblastic leukemia (ALL).
  • Indications Treatment of Philadelphia chromosome-negativ relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
  • BLINCYTO® Medication Guide

KYPROLIS® 60mg

  • Product Name (Korean) 키프롤리스주 60mg/바이알
  • Product Name (English) KYPROLIS® 60mg/vial
  • Active Ingredient (Korean) 카르필조밉
  • Active Ingredient (English) carfilzomib
  • Treatment Treatment of multiple myeloma.
  • Indications The combination therapy with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
  • KYPROLIS® Medication Guide

Prolia® Pre-filled Syringe 60mg

  • Product Name (Korean) 프롤리아® 프리필드시린지 60mg
  • Product Name (English) Prolia® Pre-filled Syringe 60mg
  • Active Ingredient (Korean) 데노수맙
  • Active Ingredient (English) denosumab
  • Treatment Treatment of osteoporosis.
  • Indications
    1. Treatment of postmenopausal women with osteoporosis.
    2. Treatment to increase bone mass in men with osteoporosis.
    3. Treatment of bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    4. Treatment of bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.
  • Prolia® Medication Guide

XGEVA® 60mg

  • Product Name (Korean) 엑스지바®주 120mg/바이알
  • Product Name (English) XGEVA® 120mg/vial
  • Active Ingredient (Korean) 데노수맙
  • Active Ingredient (English) denosumab
  • Treatment Treatment of serious bone problems in patients with bone metastases from solid tumors.
  • Indications
    1. Prevention of skeletal-related events in patients with bone metastases from solid tumors, but multiple myeloma patients are not included. Skeletal-related events refers to pathological fractures, radiation to bone, spinal cord compression, and bone surgery.
    2. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
  • XGEVA® Medication Guide